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MicroRNA-431 (miR-431) has been recognized as an oncogenic miRNA, being implicated in the ini-
tiation and development of human cancers. Recently, deregulation of miR-431 has been reported in
several tumors. However, the clinical significance of miR-431 and its underlying role in human hep-
atocellular carcinoma (HCC) are poorly explored. Herein, we found that miR-431 expression was
reduced in HCC tissues compared to noncancerous tissues. Otherwise, down-regulation of miR-
431 was observed in aggressive tumor tissues. The levels of miR-431 expression in HCC cell lines
were significantly lower than that in a nontransformed hepatic cell line. Clinical association analy-
ses disclosed that a low level of miR-431 was prominently associated with poor prognostic features
of HCC including venous infiltration, high Edmondson–Steiner grading and advanced tumor-node-
metastasis (TNM) tumor stage. Our in vitro studies showed that up-regulation of miR-431 expression
reduced cell invasion and migration in HCCLM3 cells. In contrast, down-regulation of miR-431
expression promoted SMMC-7721 cell invasion and migration. We found that up-regulation of
miR-431 expression decreased zinc finger E-box binding homeobox 1 (ZEB1) expression and inhib-
ited the epithelial–mesenchymal transition (EMT) with increased E-cadherin expression and
decreased vimentin expression in HCCLM3 cells. Otherwise, down-regulation of miR-431 expression
increased ZEB1 expression and promoted EMT in SMMC-7721 cells. Significantly, ZEB1 was identified
as a target of miR-431 in HCC. ZEB1 knockdown abrogated the effect of miR-431 silencing on EMT
and cell mobility in SMMC-7721 cells. In conclusion, miR-431 inhibits migration and invasion of
HCC cells by suppressing ZEB1-mediated EMT.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent
cancers with the worldwide incidence of more than 700,000 new
cases annually, and ranks as the third leading cause of cancer-
related mortality rate in the world [1–3]. Prominent progresses
have been made in the diagnosis and treatment of HCC, whilethe long-term prognosis of HCC patients remains unsatisfactory
[4,5]. Frequent intrahepatic or systemic metastasis is the culprit
for the high rate of recurrence and poor survival of HCC patients
[3]. Therefore, a comprehensive understanding of the underlying
mechanisms of HCC metastasis is of great significance which will
contribute to the identification of novel diagnosis and therapeutic
targets.
MicroRNAs (miRNAs), which are a group of endogenous short
non-coding single strand RNAs, act as important post-
transcriptional regulator of gene expression by interacting with
the 30-UTR of the targeted mRNAs [6]. And they participate in var-
ious biological processes [7–9] including cell differentiation and
development, cell proliferation and apoptosis, cell movements
and stem cell renewal. It has been widely accepted that the dereg-
ulation and dysfunction of miRNAs play a critical role in the
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has demonstrated that aberrant expression of miRNAs played a
key role in the initiation and progression of HCC [12]. However,
the exact mechanisms by which miRNAs regulate the metastasis
of HCC remain poorly understood.
MicroRNA-431 (miR-431), which was initially recognized as
nervous system specific miRNA [13], has been identified as a novel
tumor-related microRNA. Elevated expression of miR-431 was con-
firmed in colorectal cancer (CRC) and increased miR-431 expres-
sion was able to differentiate healthy controls from CRC patients
[14], suggesting the oncogenic role of miR-431 in CRC. Studies of
medulloblastoma and glioblastoma confirmed that miR-431 medi-
ated the inhibitory effect of human IFN-b on cell viability by mod-
ulating Janus-activated kinase–Signal transducers and activators of
transcription (JAK–STAT) signaling pathway [15], indicating the
inhibitory role of miR-431 in these cancers. Therefore, the exact
role of miR-431 in human cancers is dependent on the type of
human cancer. The study of HCC found that versican 30-UTR could
promoted the proliferation, migration, invasion, and colony forma-
tion of HCC cells by binding and arresting the functions of miR-431
[16]. However, the clinical significance and functional roles of miR-
431 in HCC are still not fully understood.
In the present study, we find that reduced expression of miR-
431 is observed in HCC with aggressive phenotype. The low-
expression of miR-431 is correlated with adverse clinicopatholog-
ical parameters of HCC. Furthermore, miR-431 inhibits migration
and invasion of HCC cells in vitro. MiR-431 inversely regulates
ZEB1 abundance and EMT in HCC cells. The effects of miR-431
down-regulation on EMT and cell mobility are abrogated by ZEB1
knockdown in SMMC-7721 cells. Our data uncover that miR-431
facilitates the invasive abilities of HCC cells by inhibiting
ZEB1-mediated EMT.
2. Materials and methods
2.1. Clinical samples and cell lines
86 samples of HCC and matched tumor-adjacent tissues were
obtained from the Department of General Surgery at the Taihe
Hospital, Hubei University of Medicine during JanuaryTable 1
Clinical correlation of miR-431 expression in HCC.
Clinicopathologic features Total no. of patie
n = 86
Age (y) <50 36
P50 50
Sex Male 65
Female 21
HBV Absent 28
Present 58
Serum AFP level (ng/mL) <400 32
P400 54
Tumor size (cm) <5 32
P5 54
No. of tumor nodules 1 68
P2 18
Cirrhosis Absent 36
Present 50
Venous infiltration Absent 76
Present 10
Edmondson–Steiner grading I + II 65
III + IV 21
TNM tumor stage I + II 66
III + IV 20
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetopro
* Statistically significant.2010–December 2013. The demographic features and clinico-
pathologic date were shown in Table 1. All samples were used after
obtaining informed consent from patients. Patients receiving pre-
operative chemotherapy or embolization were excluded. Intrahep-
atic spreading, venous infiltration or tumor invasion into bile ducts
were observed in 18 patients. 41 patients suffered tumor recur-
rence. The Hubei University of Medicine Ethics Committee
approved all protocols according to the Declaration of Helsinki
(as revised in Tokyo 2004).
The human HCC cell lines (SMMC-7721, Hep3B, MHCC97H and
HCCLM3) and a nontransformed hepatic cell line (LO2) (the Insti-
tute of Biochemistry and Cell Biology, Chinese Academy of
Sciences, Shanghai, China), were routinely cultured in complete
Dulbecco’s modified Eagle medium (DMEM, Gibco, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS, Gibco)
with 100 units/mL penicillin and 100 lg/mL streptomycin (Sigma,
St-Louis, MO, USA) at 37 C in a humidified containing of 5% CO2
incubator.
2.2. Real time quantitative reverse transcription-PCR (qRT-PCR)
qPCR primer against mature miRNA hsa-miR-431-5p (HmiRQ
P0499) and Homo sapiens snRNA U6 qPCR Primer (HmiRQP9001)
were obtained from Genecopoeia (Guangzhou, China). Cell lines
and frozen tumor specimens were subject to total RNA extraction
using Trizol reagent (Invitrogen, California, USA). Complementary
DNA synthesis was performed using TaqMan MicroRNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA) accord-
ing to the manufacturer’s instructions. Amplification and detection
of miR-431 and U6 were performed using a TaqMan Human
MiRNA Assay Kit (Applied Biosystems) and the ABI PRISM 7900
Sequence Detection System (Applied Biosystems). The relative
expression of miR-431 was shown as fold difference relative to U6.
2.3. Cell transfection
All miRNA vectors were purchased from Genecopoeia (Guangz-
hou, China) including miR-431 expression vector (HmiR0213-
MR04), the control vector for miR-431 (CmiR0001-MR04),
miR-431 inhibitor (HmiR-AN0499-AM04) and the negative controlnts, No. of patients P
Low miR-431 High miR-431
15 21 0.190
28 22
34 31 0.451
9 12
12 16 0.357
31 27
14 18 0.372
29 25
13 19 0.181
30 24
31 37 0.112
12 6
15 21 0.190
28 22
35 41 0.044*
8 2
27 38 0.006*
16 5
28 38 0.011*
15 5
tein; TNM, tumor-node-metastasis.
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sequences for ZEB1 siRNA duplex (sense 50-CAG UGA AAG AGA
AGG GAA UUU-30 and antisense 50-AUU CCC UUC UCU UUC ACU
GUU-30) or a nonspecific duplex oligonucleotide as a negative con-
trol (sense 50-GGA AAG ACG AUG ACG GAA AUU-30 and antisense
50-UUU CCG UCA UCG UCU UUC CUU-30) were synthesized by San-
gon Biotech (Shanghai) Co., Ltd. (Shanghai, China). The vectors
mentioned above were transfected into HCC cells using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the man-
ufacturer’s instructions.
2.4. Boyden chamber, transwell and MTT assays
The migration of HCC cells was detected by Boyden chamber
assays (NeuroProbe, Gaithersburg, MD, USA) as previously
described [17]. BioCoat Matrigel invasion chamber (Becton Dickin-
son Labware, Bedford, MA, USA) was used for Transwell cell inva-
sion assays as previously mentioned [18]. 2  103 HCC cells were
seed in 96-well plates and the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT, Roche, USA) assay was
employed to assess cell viability at 12, 24 and 36 h.
2.5. Western blot
RIPA buffer containing protease inhibitor was used for total pro-
tein extraction. Then, prepared protein samples were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–
PAGE) and transferred onto polyvinylidene fluoride (PVDF) mem-
branes. The membrane was blocked with 5% skimmed milk in TBST
and incubated with the appropriate antibody. The following pri-
mary antibodies were used: ZEB1 (D80D3, #3396; Cell Signaling,
Beverly, MA, USA), E-cadherin (24E10, #3195; Cell Signaling, Bev-
erly, MA, USA), vimentin (C-20, sc-7557; Santa Cruz, CA, USA)
and GAPDH (sc-25778, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (Bio-Rad, Hercules, CA, USA) were used at an appropriateFig. 1. The expression levels of miR-431 in HCC tissues and cells. Comparing differences i
tissues (n = 86), (B) aggressive (n = 18) and nonaggressive tumor tissues (n = 68), (C) HC
HCC cell lines with different metastatic potentials and the immortalized hepatic cell lindilution and detected using enhanced chemiluminescence regents
(Thermo Scientific, Waltham, MA, USA).
2.6. Luciferase reporter assay
Wild type (wt) ZEB1-30-untranslated region (UTR) and mutant
(mt) ZEB1-30-UTR were constructed as previously described [19].
For the luciferase reporter assay, SMMC-7721 cells were respec-
tively transfected with wt ZEB1-30-UTR and mt ZEB1-30-UTR and
subsequently transduced with corresponding miRNA vectors. The
cells were collected after 48 h. The dual-luciferase reporter assay
system (Promega, Madison, WI, USA) was used to measure Renilla
luciferase activity according to the manufacturer’s protocols.
2.7. Statistical analysis
The quantitative data are expressed as Mean ± SEM. The SPSS
statistical package for Windows Version 13 (SPSS, Chicago, IL,
USA) and GraphPad Prism 5 software (GraphPad Software, Inc,
San Diego, CA, USA) were used for statistical analysis. A Pearson
chi-squared test was applied to determine clinicopathological cor-
relations. Comparison between two or more groups was subjected
to a two-tailed Student’s t test or ANOVA when appropriate. Differ-
ence were considered significant when P < 0.05.
3. Results
3.1. Reduced expression of miR-431 is associated with aggressive HCCs
The mean level of miR-431 expression in HCC was obviously
lower than that in matched tumor-adjacent tissues (P < 0.05,
Fig. 1A). Aggressive HCCs were defined as cases with intrahepatic
spreading, venous infiltration or tumor invasion into bile ducts.
By contrast with nonaggressive HCCs, the expression of miR-431
was obviously reduced in aggressive cases (P < 0.05, Fig. 1B). Other-
wise, the expression of miR-431 was significantly decreased inn the expression levels of miR-431 between (A) HCC (n = 86) and matched nontumor
C tissues arising from recurrent (n = 41) and non-recurrent groups (n = 45), and (D)
e LO2 (n = 6). ⁄P < 0.05.
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Fig. 1C). Taken together, reduced expression of miR-431 was asso-
ciated with aggressive HCCs. Next, we found that miR-431 was
obviously down-regulated in HCC cells compared with normal
hepatic cells (P < 0.05, Fig. 1D). In addition, the expression of
miR-431 in highly invasive HCC cell lines, MHCC97H and HCCLM3,
were obviously lower than those in low invasive ones including
SMMC-7721 and Hep3B (P < 0.05, Fig. 1D). These results demon-
strate that reduced expression of miR-431 facilitates metastatic
behavior of HCC cells.
3.2. Clinical significance of miR-431 expression in HCC
HCC cases were divided into miR-431 low expression group
(n = 43) and high expression group (n = 43) in accordance with
the cutoff value, which was defined as the median level of miR-
431 expression in this cohort. HCC patients with venous infiltration
(P = 0.044), high Edmondson–Steiner grading (P = 0.006) and
advanced TNM tumor stage (P = 0.011) showed a significant lowerFig. 2. MiR-431 reduces migration and invasion of HCC cells. (A) HCCLM3 cells that were
qRT-PCR for miR-431 expression. Quantitative analysis indicated that miR-431 was signi
Cell migration as measured by Boyden chamber assays was inhibited by up-regulation o
HCCLM3 cells conferred a less number of invaded cells as compared with control cells. n =
with negative control (NC) and miR-431 inhibiotr (anti-miR-431), respectively, were sub
miR-431 promoted cell migration and invasion in SMMC-7721 cells. n = 3 repeats withlevels of miR-431 expression (Table 1). Herein, clinical association
analyses indicate that low-expression of miR-431 is associated
with adverse clinicopathologic features of HCC.
3.3. MiR-431 inhibits migration and invasion of HCC cells
We transduced HCC cell line, HCCLM3, with miR-431 expres-
sion vector and the control vector for miR-431. The expression of
miR-431 was obviously overexpressed by miR-431 expression vec-
tor in HCCLM3 cells as assessed by qRT-PCR (P < 0.05, Fig. 2A). Cell
migration tested by Boyden chamber assays showed that overex-
pression of miR-431 led to a significant reduction of migrated cell
numbers in HCCLM3 cells (P < 0.05, Fig. 2B). Otherwise, Transwell
assays indicated that the number of invaded HCCLM3 cells was
obviously decreased after overexpression of miR-431 (P < 0.05,
Fig. 2B). Next, miR-431 down-regulating SMMC-7721 cells was
established and measured by qRT-PCR (P < 0.05, Fig. 2C). On the
contrary, knockdown of miR-431 evidently promoted migration
and invasion of SMMC-7721 cells (P < 0.05, respectively, Fig. 2D).transfected with miR-control (control) and miR-431, respectively, were subjected to
ficantly up-regulated by miR-431 expression vectors in HCCLM3. n = 6, ⁄P < 0.05. (B)
f miR-431 in HCCLM3 cells as compared with control cells. MiR-431 overexpressing
3 repeats with similar results, ⁄P < 0.05. (C) SMMC-7721 cells that were transfected
jected to qRT-PCR for miR-431 expression. n = 6, ⁄P < 0.05. (D) Down-regulation of
similar results, ⁄P < 0.05.
Fig. 3. MiR-431 inversely regulates ZEB1 expression and EMT in HCC cells. Representative western blot indicated that up-regulation of miR-431 decreased ZEB1 expression
and inhibited EMT with elevated expression of E-cadherin and reduced expression of vimentin in HCCLM3 cells. Meanwhile, down-regulation of miR-431 increased ZEB1
expression and promoted EMT in SMMC-7721 cells. n = 6, ⁄P < 0.05.
Fig. 4. ZEB1 is identified as a functional target of miR-431 in HCC. (A) miR-431 and its putative binding sequence in the 30-UTR of ZEB1. The mutant miR-431 binding site was
generated in the complementary site for the seed region of miR-431 (wt, wild type; mt, mutant type). (B) MiR-431 significantly suppressed the luciferase activity that carried
wt but not mt 30-UTR of ZEB1. Anti-miR-431 led to a noticeable increase in luciferase activity of wt 30-UTR of ZEB1. n = 3 repeats with similar results, ⁄P < 0.05.
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nificantly changed after manipulating miR-431 expression levels in
both HCCLM3 and SMMC-7721 cells (P > 0.05, respectively, Fig. S1).
Taken together, miR-431 inhibits migration and invasion of HCC
cells.3.4. MiR-431 suppresses ZEB1-induced EMT in HCC cells
To uncover the underlying mechanisms by which miR-431
exert its functional role in HCC cells, we searched two publicly
available databases (TargetScan 6.2 and miRanDa) for the
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in HCC, was found to be one of the predicted targets of miR-431.
HCCLM3 cells that were transduced with miR-control or miR-431
were subjected to WB for ZEB1 and EMT markers. As shown in
Fig. 3, overexpression of miR-431 significantly reduced the expres-
sion of ZEB1 protein and resulted in increase of E-cadherin level
and decrease of vimentin level in HCCLM3 cells (P < 0.05, respec-
tively, Fig. 3). In contrast, knockdown of miR-431 increased the
level of ZEB1 protein and led to decrease of E-cadherin expression
and increase of vimentin expression (P < 0.05, respectively).
Herein, a dual-luciferase reporter assay was performed to disclose
whether miR-431 directly binds to the 30-UTR of ZEB1 mRNA. As
expected, miR-431 obviously reduced the luciferase activity of
ZEB1 containing a wt 30-UTR (P < 0.05, Fig. 4A and B). While an
increase in the luciferase activity of wt ZEB1 30-UTR was observed
after anti-miR-431 tranfection (P < 0.05, Fig. 4A and B). However,
there were no significant changes of the luciferase activity of
ZEB1 with an mt 30-UTR after corresponding miRNA vectors trans-
fection (Fig. 4A and B). Notably, ZEB1 knockdown by a specific
siRNA abolished the effect of miR-431 down-regulation on EMT
with elevated expression of E-cadherin and reduced expression
of vimentin in SMMC-7721 cells (P < 0.05, respectively, Fig. 5A).
And ZEB1 knockdown abrogated the effect of miR-431 silencing
on SMMC-7721 cell mobility with reduced abilities of cell migra-
tion and invasion (P < 0.05, respectively, Fig. 5B). Thus, our results
indicate that ZEB1 is a functional target of miR-431 in HCC.Fig. 5. MiR-431 inhibits EMT by targeting ZEB1 in HCC cells. MiR-431 silenced SMMC-77
were subjected to Western blot and Transwell assays. (A) ZEB1 knockdown led to up-r
vectors transfected SMMC-7721 cells. Otherwise, ZEB1 deletion abolished the effect of mi
expression of vimentin in SMMC-7721 cells. n = 6; ⁄P < 0.05. (B) ZEB1 knockdown red
knockdown abrogated the effect of miR-431 silencing on SMMC-7721 cell mobility with4. Discussion
Several studies have demonstrated that miRNAs regulate the
expression of oncogene or tumor suppressor, suggesting a new
mechanism involved in the initiation and development of HCC
[20]. Aberrant expression of miR-431 in other human cancers pro-
moted us to determine its expression status in HCC. Thus, 86
paired of HCC and matched tumor-adjacent tissues were subjected
to qRT-PCR for miR-431 expression. Our data revealed that the
expression of miR-431 in HCC was significantly lower than that
in tumor-adjacent tissues. Moreover, the expression of miR-431
was significantly reduced in aggressive HCCs as compared with
that in nonaggressive tumors. Otherwise, miR-431 was expressed
at significant lower levels in HCC cell lines, especially MHCC97H
and HCCLM3, as compared with L02. Importantly, our data showed
that reduced expression of miR-431 was associated with adverse
prognostic features of HCC. Notably, miR-431 has been considered
as a potent biomarker of human HCC with high prognostic value
[21]. Altogether, our results indicate that the status of miR-431
may be critical for prognosis determination in HCC patients.
Our gain- and loss-of-function experiments demonstrated that
overexpression of miR-431 inhibited migration and invasion of
HCCLM3 cells. While knockdown of miR-431 led to increase of
migrated and invaded SMMC-7721 cells. However, the HCC cell
viability was not significantly changed after manipulating miR-
431 expression levels. These results indicate that miR-431 truly21 cells and control cells that were transfected with scrambled siRNA or ZEB1 siRNA
egulation of E-cadherin and down-regulation of vimentin in negative control (NC)
R-431 down-regulation on EMT with elevated expression of E-cadherin and reduced
uced cell migration and invasion in control SMMC-7721 cells. Furthermore, ZEB1
reduced abilities of cell migration and invasion. n = 3; ⁄P < 0.05.
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anism hijacked by hypoxic cancer cells for metastasis [22,23]. The
term EMT has been coined to define the conversion process of
epithelial cells into migratory and invasive fibroblastoid cells,
mostly characterized by loss of epithelial cell properties, acquisi-
tion of mesenchymal cell phenotype, and enhancement of HCC cell
migration and invasion capability [24,25]. Next, we determined the
effect of miR-431 alteration on EMT makers, E-cadherin and
vimentin in HCC cells. Western blot analyses found that overex-
pression of miR-431 suppressed EMT with increase of E-cadherin
protein and decrease of vimentin protein in HCCLM3 cells. On
the contrary, down-regulation of miR-431 facilitated EMT in
SMMC-7721 cells. In summary, miR-431 may inhibit cell migration
and invasion by suppressing EMT in HCC. Recent studies reported
that down-regulation of miR-431 increase cell invasion and migra-
tion in HepG2 cells [16]. ZEB1 has been considered as a crucial reg-
ulator of EMT in HCC [26]. Accordingly, we investigated whether
miR-431 plays a regulatory role in ZEB1 expression in HCC. Our
data indicated that ZEB1 abundance was inversely associated with
miR-431 alteration in HCC cells. Herein, we validated ZEB1 as a
direct target of miR-431 in HCC. Importantly, the regulatory effects
of miR-431 knockdown on EMT progression, cell migration and
invasion were partially abrogated by ZEB1 knockdown in HCC cells.
Thus, we propose that miR-431 inhibits HCC cell migration and
invasion by suppressing ZEB1 induced-EMT.
In summary, we find that down-regulation of miR-431 is
observed in HCC tissues and cells, especially in aggressive HCCs
and highly metastatic cell lines. In addition, the low-expression
of miR-431 is associated with poor prognostic features of HCC.
We prove that miR-431 inhibits migration and invasion of HCC
cells by suppressing ZEB1-induced EMT. In conclusion, we suggest
that miR-431 functions as a tumor suppressive miRNA, and inhibits
the invasive behavior of HCC by inhibiting ZEB1.
5. Conclusions
In summary, our study discloses that the expression of miR-431
is down-regulated in HCC tissues as compared matched tumor-
adjacent tissues. Furthermore, miR-431 is expressed at significant
higher levels in aggressive and recurrent HCCs. The relative expres-
sion of miR-431 in HCC cell lines is significantly lower than that in
the normal hepatic cell line. In vitro studies demonstrate that miR-
431 inhibits migration and invasion of HCC cells. Importantly, our
data indicate that miR-431 inversely regulates the abundance of
ZEB1 and EMT progression in HCC cells. Herein, ZEB1 is identified
as a direct downstream target of miR-431. Notably, the effects of
miR-431 down-regulation on EMT, cell migration and invasion
are abrogated by ZEB1 knockdown in SMMC-7721 cells. This study
reveals that miR-431 may play a critical role in the tumor metasta-
sis of HCC and may be a potential therapeutic target for HCC.
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